Approval sNDA Letter Busulfex... ONLY (COR-SNDAACTION-05).pdf

First Page		Document Content
Date: 2011-06-29 11:23:25 Transplantation medicine Orphan drugs Stem cells Busulfan Hematopoietic stem cell transplantation Myelodysplastic syndrome Chemotherapy Total body irradiation Leukemia Medicine Alkylating antineoplastic agents Myeloid leukemia		Approval sNDA Letter Busulfex... ONLY (COR-SNDAACTION-05).pdf Add to Reading List Source URL: www.accessdata.fda.gov Download Document from Source Website File Size: 217,13 KB Share Document on Facebook

	ブスルフェクス長期予後調査 Long-term follow-up of intravenous busulfan 1．解析対象 Subjects for analyses 対象は全国調査に登録された同種移植のうち、2006 年 10 月 10 日から 2013 DocID: 1jn6l - View Document
	IV. ブスルフェクス長期予後調査 IV. Long-term follow-up of intravenous busulfan 1．解析対象 Subjects for analyses DocID: 1gYdx - View Document
	administration of cytoxan cytoxan dose for breast cancer, fludarabine and cytoxan and follicular lymphoma busulfan cytoxan vp16. cytoxan teatment for dry eyes uric counts cytoxan, infusion rate for cytoxan. cytoxan predn DocID: 1fKBX - View Document
	Reset Form Please complete, print and submit. Busulfan Information: Mail-In Specimen Instructions DocID: 1cjQU - View Document
	KLASSIFICERING AV CYTOSTATIKA (Generiskt namn) 1. Alkylerande medel BCNU, Karmustin Busulfan CCNU, Lomustin DocID: 1aI9Z - View Document